Honasa Consumer to Acquire Majority Stake in Fluence Pharma for ₹1.35 Billion Enterprise Value

GURUGRAM, India — Honasa Consumer Limited, India’s largest digital-first beauty and personal care (BPC) company, has officially approved the strategic acquisition of a majority 58% stake in Fluence Pharma Private Limited. The transaction values Fluence Pharma at an enterprise value of ₹1.35 billion (1.35 billion Indian rupees). Announced on June 23, 2026, this development marks Honasa Consumer's formal entry into the specialized "inside-out" holistic beauty and nutritional supplements segment through the establishment of a dedicated subsidiary, Honasa Health Private Limited.

Strategic Entry Into India's ₹16,000 Crore Nutraceuticals Space

Through this corporate action, Honasa Consumer widely recognized for its digital-first house of brands including Mamaearth, The Derma Co., and Aqualogica is moving beyond topical skin and hair care applications. The acquisition targets India’s rapidly growing nutraceuticals sector, which is currently valued at over ₹16,000 crore.

Fluence Pharma is a science-backed nutraceuticals manufacturer known within the medical community for its patented Cyclical Nutrition Therapy (CNT) and a deeply entrenched, dermatologist-led distribution network. By integrating Fluence's clinical research with its own digital-first marketing and multi-channel reach, Honasa aims to scale a highly differentiated business-to-consumer (B2C) portfolio.

Market Impact and Corporate Restructuring

The acquisition is structured to benefit various stakeholders across the fast-moving consumer goods (FMCG) and wellness sectors:

• Investors and Shareholders: The expansion into wellness supplements opens a high-margin revenue stream. This aligns with Honasa's long-term corporate growth strategy, following strong financial returns in previous quarters including a 177% year-on-year jump in net profits earlier in the fiscal year.

• Consumers: Regular buyers of personal care products will gain access to integrated healthcare and wellness solutions, bridging the gap between topical treatments (lotions, serums) and internal systemic nutrition.

• Retail and Business Partners: Fluence Pharma’s existing network of dermatologists and healthcare practitioners will merge with Honasa’s extensive omni-channel footprint, expanding B2B opportunities across physical and digital retail setups.

Official Sources Section

According to regulatory filings submitted to the National Stock Exchange of India (NSE), the Board of Directors of Honasa Consumer Limited approved the transaction, evaluating Fluence Pharma at an enterprise value of ₹1.35 billion. The transition will see the operational assets managed under the newly formed corporate umbrella of Honasa Health Private Limited.

Executive Quotes

In an official statement released to exchange desks, Varun Alagh, Co-founder and Chief Executive Officer (CEO) of Honasa Consumer Limited, detailed the long-term vision behind the transaction:

"The beauty and personal care landscape is entering a new era where consumers are increasingly seeking holistic, inside-out solutions that address beauty concerns at their root. While the last decade was shaped by topical actives, we believe the next decade will be defined by the powerful convergence of science-backed skin and hair care, and nutraceuticals."

Why It Matters

The acquisition highlights a broader shift in the consumer goods market, where the boundaries between medical dermatological treatment, daily skincare, and dietary supplementation are dissolving. For businesses, it sets a precedent for rapid portfolio diversification via targeted acquisitions of science-backed pharmaceutical niches rather than relying solely on organic product development. For consumers, it increases the availability of clinically validated nutrition products through standard online retail channels.

Key Facts at a Glance

• Transaction Value: ₹1.35 billion enterprise value for a 58% majority stake.

• Acquired Entity: Fluence Pharma Private Limited, specialists in Cyclical Nutrition Therapy (CNT).

• New Subsidiary: Honasa Health Private Limited created to drive the wellness portfolio.

• Target Industry Size: Indian nutraceuticals market valued at more than ₹16,000 crore.

FAQ Section

Q: What is the primary reason behind Honasa Consumer acquiring Fluence Pharma?

A: The acquisition allows Honasa Consumer to expand outside of standard cosmetics and topical skincare into the high-growth wellness and nutritional supplement market, providing an "inside-out" approach to consumer health and beauty.

Q: How much did Honasa Consumer pay for the stake?

A: The acquisition was approved based on an overall enterprise value of ₹1.35 billion for Fluence Pharma Private Limited.

Q: Will current Fluence Pharma products remain available to consumers?

A: Yes. Honasa plans to scale the existing B2C nutrition portfolio by leveraging its extensive digital-first distribution ecosystem and brand-building infrastructure.

Q: What is Cyclical Nutrition Therapy (CNT)?

A: It is Fluence Pharma's patented approach to clinical nutrition designed to address consumer nutrient gaps and health requirements systematically.

Sources:

• Corporate Disclosure and Press Release, National Stock Exchange of India (NSE)

• M&A Regulatory Filings, Thomson Reuters Financial Platform